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Abstract
Background: To evaluate real-world pharmacologic treatment of mixed dyslipidemia in patients
with diabetes mellitus (DM).
Methods: All commercial health plan members in a large US managed care database with
complete lipid panel results (HDL-C, LDL-C, TG) between 1/1/2006 and 12/31/2006 were
identified (N = 529,236). DM patients (N = 53,679) with mixed dyslipidemia were defined as having
any 2 suboptimal lipid parameters (N = 28,728). Lipid treatment status 6 months pre- and post-
index date was determined using pharmacy claims for any lipid therapy.
Results: Post-index, 41.1% of DM patients with 2 abnormal lipid parameters and 45.1% with 3
abnormal lipid parameters did not receive lipid-modifying treatment. Post-index treatment rates
were 57.4%, 63.6%, and 66.4% for patients with LDL-C, HDL-C, and TG in the most severe
quartiles, respectively. Statin monotherapy was the primary lipid-modifying regimen prescribed
(54.8% and 47.8% of patients with any 2 and all 3 lipids not at goal, respectively). Less than 30% of
treated patients received combination therapy.
Conclusion: Over 40% of DM patients with mixed dyslipidemia received no lipid-modifying
therapy during the follow-up period. Those who were treated were primarily prescribed statin
monotherapy. This study suggests that DM patients are not being treated to ADA-suggested
targets.
Introduction
Cardiovascular disease (CVD) is a primary cause of
morbidity and mortality among patients with hyperglyce-
miaortype2diabetesmellitus(DM)despitetheavailability
of effective therapies to treat major risk factors such as
elevated blood pressure and cholesterol levels [1,2].
The most common lipid pattern in patients with DM,
hypertension, and/or the metabolic syndrome includes
hypertriglyceridemia, increased concentrations of small
dense low-density lipoprotein particles, low levels of high-
densitylipoproteincholesterol(HDL-C),increasedremnant
lipoproteins, and elevated apolipoprotein B concentrations
[3,4]. This profile of mixed dyslipidemia significantly
increases risk for all forms of atherosclerotic disease,
including coronary heart disease (CHD) [5-8].
The burgeoning prevalence of insulin resistance through-
out the world is greatly increasing the incidence of mixed
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patients with coronary artery disease have low-density
lipoprotein cholesterol (LDL-C) levels below 130 mg/dL
yet these patients also have low levels of HDL-C, with or
without increased levels of triglycerides (TG) [9,10].
Overall, isolated low HDL-C affects 20% to 30% of
patients with CHD, representing several million people
in the United States [9,10].
Observational studies indicate that low HDL-C levels are
strongly and independently associated with increased
CHD risk [11-13]. The results of the first major clinical
trial specifically focusing on the treatment of low HDL-C
demonstrated that lipid treatment that raised HDL-C and
l o w e r e dT Gb u th a dn oe f f e c to nL D L - Cs u b s t a n t i a l l y
reduced the incidence of major cardiac and cerebrovas-
cular events [14].
Elevated serum levels of TG are an independent risk
factor for CHD even after adjustment for HDL-C [7]. In a
subanalysis of the Pravastatin or Atorvastatin Evaluation
and Infection Therapy-Thrombolysis In Myocardial
Infarction 22 (PROVE-IT TIMI 22) trial to assess the
impact of low on-treatment TG on CHD risk beyond
LDL-C < 70 mg/dL, Miller et al. [15] demonstrated that
on-treatment TG below 150 mg/dL was independently
associated with a lower risk of recurrent CHD events. The
Veterans Affairs HDL Intervention Trial (VA-HIT), which
included patients with low HDL-C (mean 31 mg/dL) and
LDL-C (mean 111 mg/dL), found that patients receiving
gemfibrozil had a 22% relative risk reduction in the
primary end point of time to first nonfatal myocardial
infarction or CHD death (95% CI 7% to 35%, p =
0.006). There was also a significant reduction in
cerebrovascular events. Among 627 patients with DM,
there was a 24% relative risk reduction for the expanded
end point (CHD-related death, nonfatal myocardial
infarction, or definite stroke). Likewise, among 1,449
patients with ≥ 3 criteria that define the metabolic
syndrome (impaired fasting glucose; hypertension;
obesity; high TG; or low HDL-C), the relative risk
r e d u c t i o nw i t hg e m f i b r o z i lw a sa ne v e nm o r ei m p r e s s i v e
35% for the expanded end point [14]. Together with data
from the Helsinki Heart Study [16] and a subgroup
analysis from the Bezafibrate Infarction Prevention study
[17], these data suggest that fibrates may be particularly
effective in treating dyslipidemia in patients with the
metabolic syndrome.
Multiple guidelines writing groups advocate combina-
tion therapy for the management of multiple lipid
abnormalities (NCEP ATPIII, ADA, AHA/ACC) [18,19].
Statin-fibrate combination therapy has been found to be
more successful than statin monotherapy in achieving
therapeutic targets in dyslipidemic patients with DM or
the metabolic syndrome [20-22]. The ongoing Action to
Control Cardiovascular Risk in Diabetes (ACCORD) trial
was designed to evaluate the effect of simvastatin-
fenofibrate combination therapy on cardiovascular risk
in patients with type 2 DM [23]. The effect of statin-
niacin combination therapy on atherosclerosis progres-
sion in patients with high cardiovascular risk (CHD and
low HDL-C levels) has been evaluated in both the
Arterial Biology for the Investigation of the Treatment
Effects of Reducing Cholesterol 2 (ARBITER 2) and the
HDL Atherosclerosis Treatment (HATS) studies. These
trials demonstrated that the use of statin-niacin combi-
nation therapy is associated with stabilization of
atherosclerotic disease.
Despite the abundance of data confirming the role of
suboptimal lipoprotein levels as a risk factor for CHD
and the availability of guidelines enumerating therapeu-
tic lifestyle modifications and pharmaceutical treatment
options for the management of mixed dyslipidemia, a
substantial proportion of dyslipidemic patients remain
untreated or inappropriately treated [24,25], or patients
choose to discontinue treatment soon after it is initiated
[26]. The primary objective of the present study was to
achieve greater understanding of treatment patterns in
"real-world" patients by evaluating pharmacologic treat-
ment of DM patients with mixed dyslipidemia enrolled
in a commercial health plan. Specifically, the purpose
was to determine the proportion of DM patients with
suboptimal LDL, HDL-C, and/or TG values not being
appropriately treated with lipid-modifying medications.
Methods
Data Source
This was a retrospective claims data analysis using
medical and pharmacy data, laboratory results, and
enrollment information from a large managed health
care plan in the United States, with the largest
concentration of patients being in the southern and
midwestern regions. Claims for services provided to
members of this health plan are submitted for payment
by physicians, facilities, and pharmacies. At the time the
study was conducted, the administrative claims database
included data for approximately 14 million health plan
enrollees with both medical and pharmacy benefits. All
study data were de-identified and accessed with proto-
cols compliant with the Health Insurance Portability and
Accountability Act. Institutional Review Board approval
was therefore not required for this study.
Study Subject Identification
This study was conducted to determine lipid treatment
patterns in DM patients with mixed dyslipidemia. Study
patients included commercial health plan enrollees with
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on the same day during the time period from January 1,
2006 through December 31, 2006. An index date was set
as of the date of the first suboptimal test result or first
optimal test result. Patients were required to have been
continuously enrolled for 182 days prior to and 182 days
following the index date.
Two groups of patients were created: a subset with all
lipid values (LDL-C, HDL-C, and TG) under control
(categorized as the "optimal cohort") and another subset
with at least 1 suboptimal lipid value ("suboptimal
cohort"). The criteria for the suboptimal cohort were
developed in accordance with the National Cholesterol
Education Program (NCEP) Adult Treatment Panel
(ATP) III [19] and American Heart Association (AHA)
guidelines [13-15]. For DM/CHD patients, suboptimal
lipid values were defined as LDL-C ≥ 100mg/dL,HDL-C ≤
40 mg/dL for males and ≤ 50 mg/dL for females, and
TG ≥ 150 mg/dL.
Study Measures
Patient demographic variables (age, gender, and geo-
graphic location) were captured from the enrollment
data. Lipid lab values (LDL-C, HDL-C, TG) were
obtained from the lab results data. Study patients were
observed for 182 days prior to the index date (pre-index
period) and for 182 days after the index date (post-index
period) to determine their lipid risk factors for CVD and
their pharmaceutical prescription patterns. For the
assignment of LDL-C goal, patients were classified into
4 risk categories: (1) age/gender (male, ≥ 45 years;
female, ≥ 55 years); (2) CHD (a medical claim indicating
presence of CHD during the pre-index period); (3)
hypertension (presence of ICD-9-CM code 401.x–404.x,
642.0x–642.2x, 642.7x during the pre-index period); and
(4) DM (presence of ICD-9-CM code 250.xx or at least 2
filled prescriptions for oral antidiabetic agents during the
pre-index period).
T h ep r e s e n c eo fap h a r m a c yc l aim for any lipid therapy,
including statins, fibrates, niacin, or various combina-
tions, was determined. Specifically, separate determina-
tions were made to identify patients with the following
prescription patterns during the pre-index and post-
index periods: (1) pharmacy claim for a statin (atorvas-
tatin, cerivastatin, fluvastatin, lovastatin, pravastatin,
rosuvastatin, simvastatin, or atorvastatin + amlodipine
[Caduet
®]) and without a claim for other lipid-modify-
ing medications; (2) pharmacy claim for a fibrate
(clofibrate, gemfibrozil, fenofibrate) and without a
claim for other lipid-modifying medications; (3) phar-
macy claim for a niacin/nicotinic acid and without a
claim for other lipid-modifying medications; (4)
pharmacy claim for "other" medication (cholestyramine,
colestipol, colesevelam, ezetimibe) and without a claim
for other lipid-modifying medications; (5) pharmacy
claim for a statin and a fibrate; (6) pharmacy claim for a
statin and niacin/nicotinic acid; (7) pharmacy claim for a
statin and other lipid-modifying medication; (8) phar-
macy claim for a fibrate and a niacin; (9) pharmacy
claim for a fibrate and other medications (cholestyr-
amine, colestipol, colesevelam, ezetimibe); (10) phar-
macy claim for a niacin and other medications
(cholestyramine, colestipol, colesevelam, ezetimibe);
(11) combinations other than those already mentioned;
and (12) no claim for a lipid-modifying medication.
Analysis
All study variables were analyzed descriptively. Numbers
and percentages are provided for dichotomous and
polychotomous variables. Means, medians, standard
deviations, and percentiles are provided for continuous
variables. Differences in mean values were assessed using
a t-test and differences in proportions were assessed
using a chi-squared test.
Results
Patient Characteristics
Of the 3.9 million health plan enrollees in 2006, lab
values for LDL-C, HDL-C, and TG levels were available
for a total of 529,236 patients. Of these, 65,242 (12.3%)
met the definition of having DM, and 82.3% (n =
53,679) of the DM patients had at least 1 suboptimal
lipid value and 17.7% (n = 11,563) had optimal values
for all lipid tests The mean age of the study population
was 52 years, and was similar in the suboptimal cohort
and optimal cohort (p = 0.0725). Fifty-two percent of
patients were female and 47% were male in the study
population (Table 1).
Among the diabetes patients in the suboptimal cohort
(n = 53,679), approximately 54% (n = 28,728) had more
than 1 lipid abnormality. The lipid abnormalities in the
DM population were as follows: 23% had high LDL-C
values only, 13% had low HDL-C only, 10% had
elevated TG only, 10% had high LDL-C and low HDL-
C, 12% had elevated LDL-C and TG, 16% had low HDL-
C and elevated TG, and 16% had abnormal values for all
3 lipid fractions.
Treatments
Overall, an increase in lipid-modifying therapy from the
pre-index period to the post-index period was observed
in DM patients with mixed dyslipidemia. In the pre-
index period, 68% of DM patients with suboptimal LDL-
C and HDL-C, 58% with suboptimal LDL-C and TG,
32% with suboptimal HDL-C and TG, and 60% with
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treatment for dyslipidemia. In the post-index period, the
percentages of patients not receiving therapy decreased
to 58%, 43%, 29%, and 45% in each group, respectively.
Patients with suboptimal HDL-C and TG had the
smallest decrease in the percentage of patients not
receiving lipid-modifying therapy (Figure 1).
Among DM patients with more than 1 lipid abnormality,
25% to 37% were prescribed statin monotherapy, 3–6%
received fibrate monotherapy, and less than 1% received
niacin monotherapy during the post-index period.
Figure 2 illustrates the pre-index versus post-index
monotherapy patterns for DM patients with mixed
dyslipidemia. The proportion of DM patients treated
with statins in combination with other lipid-modifying
drugs increased from the pre-index to post-index time
period but still remained low (1.5% to 3.5% of patients
receiving statin and fibrate therapy, < 1.0% to 2.6% of
those receiving statin and niacin therapy, and 7.0% to
10.4% of those receiving statin and other lipid-modifying
therapy). Figure 3 shows the pre-index versus post-index
combination treatment patterns for this patient group.
The treatment patterns for patients with DM were also
evaluated by quartiles of suboptimal LDL-C, HDL-C, and
TG values. The ranges for the quartiles are defined in
Figure 4. A total of 32,855 patients (61%) were
identified as having elevated LDL-C, 29,398 (55%) had
low HDL-C, and 28,755 (54%) had elevated TG. Among
the patients with a suboptimal lipid value and DM, the
p e r c e n t a g e so fp a t i e n t sn o treceiving treatment were
63%, 47%, and 49%, respectively. The percentage of
patients not receiving lipid-modifying therapy decreased
in the post-index period, but remained high in every
quartile as illustrated in Figure 4. In the first quartile, the
percentages of patients not receiving treatment for
suboptimal LDL-C, HDL-C, and TG were 53%, 36%,
and 39%, respectively. In the fourth quartile, the
percentage of patients not receiving therapy decreased
to 43% for patients with suboptimal LDL levels, but
increased for patients with suboptimal HDL-C and TG
(to 46% and 40%, respectively). When treatment was
initiated, statin monotherapy was the most commonly
prescribed regardless of the type of lipid abnormality
and the quartile.
Table 1: Demographic Information for Patients with Diabetes
Demographics Total (N = 65,242) Suboptimal Cohort (N = 53,679) Optimal Cohort (N = 11,563) p-value
mean std mean std mean std
Age (continuous) 52.43 10.53 52.39 10.22 52.61 11.86 0.0725
n% n % n %
Age < 0.0001
< 45(M) or < 55(F) 22,697 34.79 19,011 35.42 3.686 31.88
> = 45(M) or > = 55(F) 42,545 65.21 34,668 64.58 7,877 68.12
Gender < 0.0001
Male 34,538 52.94 27,695 51.59 6,843 59.18
Female 30,704 47.06 25,984 48.41 4,720 40.82
Geographic Location < 0.0001
Northeast 8,695 13.33 7,061 13.15 1,634 14.13
Midwest 13,374 20.50 10,979 20.45 2,395 20.71
South 40,440 61.98 33,489 62.39 6,951 60.11
West 2,733 4.19 2,150 4.01 583 5.04
% is calculated from the Column total.
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Despite the availability of treatment guidelines for
dyslipidemia management and the abundance of clinical
trial evidence highlighting the benefits of lipid-modify-
ing therapy to reduce the risk for CHD and its clinical
sequelae, treatment of DM patients with abnormal
LDL-C, HDL-C, and TG levels continues to be
suboptimal. In our patient population, 16% of patients
with suboptimal lipid values and 21% of our mixed
dyslipidemia group had DM. Our DM patient popula-
tion had a high (> 50%) proportion of patients with
abnormal HDL-C and TG levels. This is in line with the
results of a recent study by Grant et al. [27], who also
found a high prevalence of suboptimal HDL-C among
patients with type 2 diabetes, with nearly half (49.5%) of
patients exhibiting low HDL-C. Another study, involving
a high-risk population with documented CHD or CHD
risk equivalents, also found a high prevalence of low
HDL-C across various LDL-C levels, including among
patients taking statins [28]. In that study, low HDL-C was
most prevalent in patients with LDL-C of 70 mg/dL or
lower, and was equally and highly prevalent in patients
taking statins (67%) and those not taking statins (64%).
A large percentage of DM patients with suboptimal lipid
levels in our study did not receive lipid-modifying
therapy either prior to or after a suboptimal lipid value
was obtained (53% and 42%, respectively). While the
percentage of patients receiving lipid-modifying therapy
increased in the post-index period, a substantial number
of DM patients with suboptimal lipid levels did not
receive any lipid-modifying therapy in the post-index
period irrespective of abnormal lipid parameter, or the
degree of the abnormal value. At least 30% of DM
patients with suboptimal lipid levels across all mixed
dyslipidemic groups were not treated with any lipid-
modifying medication for at least 6 months post-index.
Although lipid treatment rates increased post-index in all
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rates were correlated with the number of total risk
factors, abnormal lipid parameters and more severe lipid
value quartiles, the incremental use of lipid-modifying
medication was not as substantial as would be expected,
given the compelling association between multiple lipid
abnormalities and cardiovascular risk in patients with
DM. Of particular note is that in DM patients with low
HDL-C and elevated TG, the most common post-index
lipid therapy used was statin monotherapy (in 37% of
patients), and only 17% received any niacin or fibrate
therapy to target suboptimal HDL-C or TG. Grant et al.
[27] described similar findings, with the vast majority of
their study patients receiving statin monotherapy and a
very small percentage being prescribed treatment target-
ing the suboptimal HDL-C level.
These results are also consistent with those reported by
Klingman and colleagues [29], who evaluated data from
the 1999–2000 National Health and Nutrition Examina-
tion Survey to assess the state of dyslipidemia manage-
ment in the US adult population and to determine
whether treatment patterns were consistent with guide-
line recommendations. They demonstrated that 44% of
treatment-eligible adults had never been told by a
physician, or any other healthcare professional, that
they had dyslipidemia. Among all treatment-eligible
adults, only 30% were adopting therapeutic lifestyle
changes (TLC) and only 10% were receiving lipid-
modifying therapy. Very high percentages of treatment-
eligible adults were receiving no treatment at all for
dyslipidemia: 69% overall, 61% of high-risk adults, 70%
of medium-risk adults, and 77% of low-risk adults.
Unlike the present study, however, Klingman and
colleagues focused on the achievement of LDL-C goals
and did not evaluate HDL-C and TG levels.
Although the reasons for the suboptimal treatment of
dyslipidemia are beyond the scope of this study, several
explanations have been proposed to account for the
discrepancy between guideline recommendations and
real-world treatment patterns. These include suboptimal
patient-follow-up, use of low-potency statins in high-risk
patients, inaccurate pill counts and refill records,
patients' inability to pay for medications, lack of patient
motivation [30], physician time constraints, difficulty
understanding and applying NCEP guidelines [19], and
lingering concerns about the potential hepatic and
skeletal muscle toxicity of combinations of lipid-
modifying drugs [31].
NCEP ATPIII recommends adjunctive therapy with
niacin or fibrates (to achieve non-HDL goal) for
dyslipidemic patients with multiple CVD risk factors
who have low HDL-C and/or high TG, after the LDL-C
goal has been achieved with statin monotherapy
[7,19,32]. Our study results suggest that the majority of
patients with DM receiving lipid-modifying treatment
are being treated with statin monotherapy. Although it is
well documented that the different classes of lipid-
modifying medications have different (complementary)
effects on lipid parameters [19], statin monotherapy
continued to be prescribed to 81% of patients with more
than 1 suboptimal lipid value who received treatment
during the post-index period of our study, even though
many patients with multiple lipid abnormalities – i.e.,
those with suboptimal HDL-C and TG levels – may have
gained greater benefit from adjunctive treatment with
either niacin, a drug with the greatest capacity to increase
HDL-C, or fibrates, which have the most pronounced
capacity to decrease elevations in serum TG. This is
despite the fact that NCEP ATPIII was published in 2001,
5 years prior to the conduct of this study [19].
Our findings regarding prescribing habits for mixed
dyslipidemia are consistent with results reported by
Stacy and colleagues [33], who evaluated 600 high-
volume prescribers of lipid-modifying drugs in 6
metropolitan areas identified from the IMS Health
prescription database. Their study also found that 40%
of the study population potentially had mixed dyslipi-
demia. These investigators reported that a high percen-
tage of patients (69%) were prescribed monotherapy
with lipid-modifying medication, of which 82% was
statin monotherapy; furthermore, 14% were not pre-
scribed any lipid-modifying drug therapy.
Study Limitations
The findings of this study must be considered within the
limitations of the data and study design. Claims data are
collected for the purpose of payment and not research
and may not accurately capture a patient's medical use
history. While these data provide insight into real-world
treatment patterns, they are subject to possible coding
errors. Certain information is not readily available in
claims data that could have an effect on study outcomes,
such as certain clinical and disease-specific parameters.
Furthermore, the presence of a prescription claim does
not necessarily indicate that the drug was taken or that it
was taken as prescribed – nor does it reflect those
patients who may have received drugs without the
presence of a prescription claim either by receiving
drug samples or filling a prescription outside of the
health care pharmacy system. The presence of a diagnosis
code on a medical claim does not demonstrate positive
presence of disease, as it may be incorrectly coded or
included as a rule-out criterion rather than as an
indication of actual disease.
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managed care plan, this study may not be generalizable
to the general population and may not be applicable to a
setting outside of managed care. Finally, a limitation
specific to this study is that the description for values in
the laboratory results does not clearly indicate whether
lipid values were obtained during fasting. Although these
limitations do not reduce the strength of the study, they
must be considered when interpreting the results.
Conclusion
In real-world clinical practice, pharmacologic treatment
rates increased only slightly upon assessment of multiple
lipid abnormalities and in patients with DM. Over 42%
of DM patients with mixed dyslipidemia received no
lipid-modifying therapy after suboptimal lipid levels
were ascertained, and those patients who were treated,
even those with low HDL-C and high TG levels who may
benefit from adjunctive treatment with niacin or fibrates,
were primarily prescribed statin monotherapy. These
study results suggest DM patients are not being treated to
ADA-suggested targets. Further research is warranted to
investigate how physicians tailor lipid-modifying ther-
apy in these patients so that solutions aimed at
improving treatment rates can be devised in order to
help DM patients better achieve guideline-defined LDL-
C, HDL-C, and TG goals, thereby potentially reducing
their risk for cardiovascular events.
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